Methods and Compositions Involving (S)-Bucindolol
AssigneeARCA Biopharma, Inc.
InventorsMichael R. Bristow, Jonathan D. Port
Life of this patent
Estimating the term…
Abstract
Disclosed is bucindolol substantially free of its R-stereoisomer. Also disclosed are pharmaceutical compositions that include bucindolol substantially free of its R-stereoisomer or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. Also disclosed are methods of treating a patient that involve administering to the patient a therapeutically effective amount of a composition of the present invention.
Claims62
Bucindolol (2-(3-(1-(1H-indol-3-yl)-2-methylpropan-2-ylamino)-2-hydroxypropoxy)benzonitrile), substantially free of its R-stereoisomer.
A pharmaceutically acceptable salt of bucindolol, substantially free of its R-stereoisomer.
A pharmaceutical composition comprising a pharmaceutically acceptable carrier and bucindolol substantially free of its R-stereoisomer.
A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a pharmaceutically acceptable salt of bucindolol, substantially free of its R-stereoisomer.
A method of treating a patient comprising administering to said patient a therapeutically effective amount of a composition comprising bucindolol, wherein the composition is substantially free of the R-stereoisomer of bucindolol.
A method of increasing the capacity of a cell to generate NO, comprising contacting said cell with a composition comprising a pharmaceutically acceptable carrier and bucindolol substantially free of its R-stereoisomer.
A medical device comprising a coating, a matrix, or a chamber, wherein said coating, matrix, or chamber comprises bucindolol substantially free of the R-stereoisomer of said bucindolol.
Dependencies are inferred from the claim text.